Strategic Communication and Public Relations

DKTK Munich: “Jumping gene” uncovers genetic networks involved in prostate and breast cancer

No. 14b | 21/03/2017 | by AM

Mutations in tumor suppressor genes mean that they can no longer keep tumors from growing. In developing cancer, often several mutations come into play. Using "jumping genes," scientists from the Technical University of Munich (TUM) and the German Cancer Consortium (DKTK) together with teams from Great Britain and Spain have identified a number of genes that can influence the growth of prostate and breast tumors. They published their results in "Nature Genetics".

Prostate cancer cells under the microscope.
© Lukasz Kacprzyk / DKFZ

Prostate cancer is the most common cancer in men in Germany with around 63,000 patients diagnosed every year. About half of them have an altered Pten gene. This well-known tumor suppressor gene can help prevent cancer development in healthy people by inducing cell death in tumor cells. However, little is known about which other genes cooperate with Pten to prevent cancer.In order to find out more, the international team designed a new method. They converted the Pten-Gene in mice into a mobile DNA element known as a transposon. This transposon "jumps" from its original position and lands at a random position throughout the genome, damaging and thus deactivating genes into which it is inserted. The transposons "starting point", i.e. the Pten-Gene, is deactivated as well. In the experiment, cancers would grow when the transposon damaged a tumor suppressor gene that co-operated with Pten.

"Using the new transposon-based approach, we were able to systematically search the genome for genes cooperating with Pten and influencing the development of prostate cancer, but also other forms of cancer like breast or brain cancer," says Dr Juan Cadiñanos, joint lead author from the Instituto de Medicina Oncologica y Molecular de Asturias and the Wellcome Trust Sanger Institute in Britain. "This approach could also be used to look into relations between other genes."

The researchers analysed 278 prostate, breast and skin tumors and revealed hundreds of genes that could cooperate with Pten and act as further tumor suppressor genes. Human cell lines and data from human prostate tumors were then used to study the five most promising genes."Coupled with Pten inactivation, a loss of function in these genes led to typical cancer pathways being activated," says Jorge de la Rosa, one of the study's first authors. The researchers found that in human prostate tumors, the genes in question were considerably limited in their function.

Transposon-based approaches are useful for looking into the molecular basics of the development of tumors. "They allow us to find genes connected to cancer that are hard to find using other methods," says Roland Rad, a DKTK-Professor for translational Oncology at TUM's Klinikum rechts der Isar. "In order to understand the biology of tumor development, we must uncover the complex tumor suppressor networks. This is a prerequisite for developing new therapeutic strategies."

Original publication:
de la Rosa et. al.*: A single-copy Sleeping Beauty transposon mutagenesis screen identifies new PTEN-cooperating tumor suppressor genes. In: Nature Genetics (20. März 2017) doi:10.1038/ng.3817

* The two first and four last authors have contributed equally to this publication.

The German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ) with its more than 3,000 employees is the largest biomedical research institution in Germany. More than 1,300 scientists at the DKFZ investigate how cancer develops, identify cancer risk factors and search for new strategies to prevent people from developing cancer. They are developing new methods to diagnose tumors more precisely and treat cancer patients more successfully. The DKFZ's Cancer Information Service (KID) provides patients, interested citizens and experts with individual answers to all questions on cancer.

Jointly with partners from the university hospitals, the DKFZ operates the National Center for Tumor Diseases (NCT) in Heidelberg and Dresden, and the Hopp Children's Tumour Center KiTZ in Heidelberg. In the German Consortium for Translational Cancer Research (DKTK), one of the six German Centers for Health Research, the DKFZ maintains translational centers at seven university partner locations. NCT and DKTK sites combine excellent university medicine with the high-profile research of the DKFZ. They contribute to the endeavor of transferring promising approaches from cancer research to the clinic and thus improving the chances of cancer patients.

The DKFZ is 90 percent financed by the Federal Ministry of Education and Research and 10 percent by the state of Baden-Württemberg. The DKFZ is a member of the Helmholtz Association of German Research Centers.


Subscribe to our RSS-Feed.

to top
powered by webEdition CMS